{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:39:11Z","timestamp":1762864751611},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.bpg.2003.11.004","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T12:48:18Z","timestamp":1082551698000},"page":"421-445","source":"Crossref","is-referenced-by-count":61,"title":["Progress in enteric vaccine development"],"prefix":"10.1016","volume":"18","author":[{"given":"Ann-Mari","family":"Svennerholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2003.11.004_BIB1","series-title":"State of the World's Vaccines and Immunization","author":"Davey","year":"1996"},{"key":"10.1016\/j.bpg.2003.11.004_BIB2","first-page":"291","article-title":"Vaccines against diarrheal disease","volume":"vol. 133","author":"Holmgren","year":"1998"},{"key":"10.1016\/j.bpg.2003.11.004_BIB3","series-title":"2002 report of the Steering Committee on Diarrheal Disease Vaccines, Hanoi, March 5\u20138","year":"2002"},{"key":"10.1016\/j.bpg.2003.11.004_BIB4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB5","series-title":"Vibrio cholerae and Cholera: Molecular to Global Perspectives","first-page":"293","article-title":"Historical perspectives on pandemic cholera","author":"Blake","year":"1994"},{"key":"10.1016\/j.bpg.2003.11.004_BIB6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-3156.1996.d01-54.x","article-title":"Vibrio cholerae O139: how great is the threat of a pandemic?","volume":"1","author":"Siddique","year":"1996","journal-title":"Tropical Medicine International Health"},{"key":"10.1016\/j.bpg.2003.11.004_BIB7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(95)90338-0","article-title":"Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994?","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB8","first-page":"117","article-title":"Cholera vaccines. WHO position paper","volume":"76","year":"2001","journal-title":"Weekly Epidemiological Research"},{"key":"10.1016\/j.bpg.2003.11.004_BIB9","series-title":"New Generation Vaccines","article-title":"Oral B subunit killed whole-cell cholera vaccines","author":"Holmgren","year":"2004"},{"key":"10.1016\/j.bpg.2003.11.004_BIB10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1128\/IAI.55.5.1116-1120.1987","article-title":"Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin","volume":"55","author":"Black","year":"1987","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0140-6736(90)90080-O","article-title":"Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up","volume":"335","author":"Clemens","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0264-410X(95)00122-H","article-title":"Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up","volume":"14","author":"van Loon","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(94)90755-2","article-title":"Protective efficacy of oral whole-cell\/recombinant-B-subunit cholera vaccine in Peruvian military recruits","volume":"344","author":"Sanchez","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB14","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1086\/315462","article-title":"Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru","volume":"181","author":"Taylor","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0140-6736(91)92590-X","article-title":"Prevention of travellers diarrhoea by oral B-subunit\/whole-cell cholera vaccine","volume":"338","author":"Peltola","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1708-8305.1995.tb00615.x","article-title":"Safety, immunogenicity, and protective efficacy of the whole-cell\/recombinant B subunit (WC\/rBS) oral cholera vaccine against travelers\u2019 diarrhea","volume":"2","author":"Scerpella","year":"1995","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(96)06107-7","article-title":"Field trial of a locally produced, killed, oral cholera vaccine in Vietnam","volume":"349","author":"Trach","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0020-2452(96)85758-7","article-title":"Live oral cholera vaccine: from principle to product","volume":"93","author":"Levine","year":"1995","journal-title":"Bulletin Institut Pasteur"},{"key":"10.1016\/j.bpg.2003.11.004_BIB20","series-title":"Molecular and Clinical Aspects of Bacterial Vaccine Development","first-page":"233","article-title":"Live oral vaccines against cholera","author":"Levine","year":"1995"},{"key":"10.1016\/j.bpg.2003.11.004_BIB21","unstructured":"Levine MM & Svennerholm A-M. Enteric vaccines: present and future. In DuPont HL & Steffen H (eds) Textbook of Travel Medicine and Health, 2nd edn. New York, BC Decker, 2001, pp 252\u2013263."},{"key":"10.1016\/j.bpg.2003.11.004_BIB22","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1128\/IAI.67.12.6341-6345.1999","article-title":"Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination","volume":"67","author":"Tacket","year":"1999","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/S0264-410X(00)00006-2","article-title":"Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area","volume":"18","author":"Richie","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/172.4.1126","article-title":"Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1","volume":"172","author":"Kenner","year":"1995","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/IAI.70.4.1965-1970.2002","article-title":"Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine","volume":"70","author":"Cohen","year":"2002","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB26","doi-asserted-by":"crossref","first-page":"6391","DOI":"10.1128\/IAI.68.11.6391-6397.2000","article-title":"Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision","volume":"68","author":"Chiang","year":"2000","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0264-410X(02)00412-7","article-title":"Construction and characterisation of O139 cholera vaccine candidates","volume":"21","author":"Ledon","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB28","first-page":"837","article-title":"Mass vaccination with a two-dose oral cholera vaccine in a refugee camp","volume":"77","author":"Legros","year":"1999","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.bpg.2003.11.004_BIB29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1708-8305.1995.tb00643.x","article-title":"Risk of cholera among Western and Japanese travellers","volume":"2","author":"Wittlinger","year":"1995","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB30","unstructured":"World Health Organization. Background document: The diagnosis, treatment and prevention of typhoid fever, WHO Report V & B, 03.07.2003."},{"key":"10.1016\/j.bpg.2003.11.004_BIB31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00006454-200105000-00010","article-title":"Typhoid fever in Bangladesh: implications for vaccination policy","volume":"20","author":"Saha","year":"2001","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.bpg.2003.11.004_BIB32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJM198710293171801","article-title":"Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report","volume":"317","author":"Acharya","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0264-410X(95)00186-5","article-title":"Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization","volume":"14","author":"Klugman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0264-410X(98)00160-1","article-title":"Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization","volume":"17","author":"Keddy","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB35","first-page":"625","article-title":"Efficacy trial of Vi polysaccharide vaccine against typhoid fever in South western China","volume":"79","author":"Yang","year":"2001","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.bpg.2003.11.004_BIB36","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two to five years old children","volume":"344","author":"Lin","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2003.11.004_BIB38","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0264-410X(99)00231-5","article-title":"Duration of efficacy of Ty21a attenuated Salmonella typhi live oral vaccine","volume":"17","author":"Levine","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.68.3.1196-1201.2000","article-title":"Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908 htrA in U.S. volunteers","volume":"68","author":"Tacket","year":"2000","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/173.6.1408","article-title":"phoP\/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers","volume":"173","author":"Hohmann","year":"1996","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB41","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/IAI.70.7.3457-3467.2002","article-title":"Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers","volume":"70","author":"Hindle","year":"2002","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB42","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation","volume":"77","author":"Kotloff","year":"1999","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.bpg.2003.11.004_BIB43","doi-asserted-by":"crossref","first-page":"G319","DOI":"10.1152\/ajpgi.2001.280.3.G319","article-title":"Microbes and microbial toxins: paradigms for microbial\u2013mucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis","volume":"280","author":"Sansonetti","year":"2001","journal-title":"American Journal of Physiology and Gastrointesinal Liver Physiology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB44","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1365-2958.2000.02179.x","article-title":"The virulence plasmid pWR 100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri","volume":"38","author":"Buchrieser","year":"2000","journal-title":"Molecular Microbiology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/infdis\/171.2.376","article-title":"Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma","volume":"171","author":"Raqib","year":"1995","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB46","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1128\/IAI.64.10.4074-4077.1996","article-title":"Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers","volume":"64","author":"Cohen","year":"1996","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.bpg.2003.11.004_BIB49","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/IAI.61.6.2390-2395.1993","article-title":"Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models","volume":"61","author":"Orr","year":"1993","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0264-410X(95)80017-8","article-title":"Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL 1070 with a deleted aroD gene in adult Swedish volunteers","volume":"13","author":"K\u00e4rnell","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB51","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1128\/IAI.64.11.4542-4548.1996","article-title":"Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG","volume":"64","author":"Kotloff","year":"1996","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB52","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/IAI.68.3.1034-1039.2000","article-title":"Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans","volume":"68","author":"Kotloff","year":"2000","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB53","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB54","series-title":"New Generation Vaccines","article-title":"Oral inactivated whole cell B subunit combination vaccine against enterotoxigenic Escherichia coli","author":"Svennerholm","year":"2004"},{"key":"10.1016\/j.bpg.2003.11.004_BIB55","unstructured":"Wenner\u00e5s C & Erling V. Global distribution of enterotoxigenic Escherichia coli (ETEC): epidemiology and virulence factors. World Health Organization Report; in press."},{"key":"10.1016\/j.bpg.2003.11.004_BIB56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0966-842X(96)10068-8","article-title":"Colonization factors of human enterotoxigenic Escherichia coli (ETEC)","volume":"4","author":"Gaastra","year":"1996","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0264-410X(02)00613-8","article-title":"Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen","volume":"21","author":"Katz","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB58","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1128\/IAI.70.4.1874-1880.2002","article-title":"Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously","volume":"70","author":"Guerena-Burgueno","year":"2002","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB59","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1128\/IAI.66.7.3311-3316.1998","article-title":"Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood","volume":"66","author":"\u00c5hr\u00e9n","year":"1998","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB60","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/517812","article-title":"Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli\u2013cholera toxin B subunit vaccine in Egyptian adults","volume":"177","author":"Savarino","year":"1998","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB61","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/S0264-410X(00)00056-6","article-title":"Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children","volume":"18","author":"Qadri","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB62","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00006454-200204000-00012","article-title":"Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants","volume":"21","author":"Savarino","year":"2002","journal-title":"Pediatric Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB63","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/S0264-410X(03)00077-X","article-title":"Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18\u201336 months of age","volume":"21","author":"Qadri","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB64","first-page":"727","article-title":"Double-blind, randomised, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers diarrhea (preliminary report)","author":"Wiedermann","year":"2000","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB65","series-title":"Safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhea in adult travelers to Guatemala and Mexico","author":"Sack","year":"2002"},{"key":"10.1016\/j.bpg.2003.11.004_BIB66","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1128\/IAI.69.5.3150-3158.2001","article-title":"Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection","volume":"69","author":"Altboum","year":"2001","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0264-410X(02)00611-4","article-title":"Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuate Shigella vaccine strains","volume":"21","author":"Barry","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB68","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1128\/IAI.69.8.4969-4979.2001","article-title":"Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans","volume":"69","author":"Turner","year":"2001","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.bpg.2003.11.004_BIB69","first-page":"2207","article-title":"Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries","volume":"17","author":"Bresse","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB70","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3201\/eid0905.020562","article-title":"Global illness and deaths caused by rotavirus disease in children","volume":"9","author":"Parashar","year":"2003","journal-title":"Emerging Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB71","series-title":"Field's Virology","first-page":"1787","article-title":"Rotaviruses","author":"Kapikian","year":"2001"},{"key":"10.1016\/j.bpg.2003.11.004_BIB72","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0264-410X(02)00616-3","article-title":"and the African Rotavirus Network. Rotavirus strains circulating in Africa. The emergence of G9 and P[6] strains","volume":"21","author":"Steele","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB73","first-page":"525","article-title":"Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization","volume":"76","author":"Cunliffe","year":"1998","journal-title":"Bulletin of the World Health Organisation"},{"key":"10.1016\/j.bpg.2003.11.004_BIB74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0300985871008005-00612","article-title":"Pathology of neonatal calf diarrhoea induced by a reo-like virus","volume":"8","author":"Mebus","year":"1974","journal-title":"Veterinary Pathology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0021-9975(77)90026-3","article-title":"Pathological changes in the small intestine of neonatal pigs infected with a pig reo-like agent (rotavirus)","volume":"87","author":"Pearson","year":"1977","journal-title":"Journal of Comparative Pathology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1126\/science.272.5258.101","article-title":"Age-dependent diarrhoea induced by a rotaviral non-structural glycoprotein","volume":"272","author":"Ball","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bpg.2003.11.004_BIB77","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(73)92867-5","article-title":"Virus particles in epithelial cells of duodenal mucosa of children with gastroenteritis","volume":"ii","author":"Bishop","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB78","series-title":"Field's Virology","first-page":"1747","article-title":"Rotaviruses and their replication","author":"Estes","year":"2001"},{"key":"10.1016\/j.bpg.2003.11.004_BIB79","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/infdis\/174.Supplement_1.S30","article-title":"Review of G and P typing results from a global collection of rotavirus strains; implications for vaccine development","volume":"174","author":"Gentsch","year":"1996","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB80","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJM198307143090203","article-title":"Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children","volume":"309","author":"Bishop","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB81","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJM199610033351404","article-title":"Rotavirus infection in infants as protection against subsequent infections","volume":"335","author":"Velazquez","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB82","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/342294","article-title":"Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea Bissau, West Africa","volume":"186","author":"Fischer","year":"2002","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB83","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/CMR.9.3.423","article-title":"Rotavirus vaccines: an overview","volume":"9","author":"Midthun","year":"1996","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.bpg.2003.11.004_BIB84","series-title":"The Vaccine Book","first-page":"225","article-title":"Rotavirus","author":"Bresee","year":"2003"},{"key":"10.1016\/j.bpg.2003.11.004_BIB85","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1093\/infdis\/174.Supplement_1.S65","article-title":"Efficacy of a quadrivalent rhesus rotavirus-based vaccine aimed at preventing severe rotavirus diarrhoea in infants and young children","volume":"174S","author":"Kapikian","year":"1996","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB86","first-page":"7","article-title":"Safety and efficacy of the high dose rhesus\u2013human reassortant rotavirus vaccines: report of the national multicentre trial","volume":"97","author":"Rennels","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.bpg.2003.11.004_BIB87","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(97)05118-0","article-title":"Randomised placebo controlled trial of the rhesus\u2013human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis","volume":"350","author":"Joensuu","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB88","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJM199710233371701","article-title":"Efficacy of the rhesus rotavirus based on quadrivalent vaccine in infants and young children in Venezuela","volume":"337","author":"Perez-Schael","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB89","first-page":"1","article-title":"Rotavirus Vaccines for the prevention of rotavirus gastroenteritis among children\u2014Recommendations of the Advisory Committee on Immunization Practices","volume":"48","year":"1999","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.bpg.2003.11.004_BIB90","first-page":"577","article-title":"Intussusception among recipients of rotavirus vaccine\u2014United States \u20131999","volume":"48","year":"1998","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.bpg.2003.11.004_BIB91","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1086\/367895","article-title":"Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions","volume":"187","author":"Murphy","year":"2003","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB92","doi-asserted-by":"crossref","first-page":"s73","DOI":"10.1093\/infdis\/174.Supplement_1.S73","article-title":"The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants","volume":"174S","author":"Clark","year":"1996","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB93","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/jama.273.15.1191","article-title":"Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group","volume":"273","author":"Bernstein","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.bpg.2003.11.004_BIB94","first-page":"172","article-title":"Preliminary evaluation of safety and efficacy of quadrivalent human\u2013bovine reassortant rotavirus vaccine","volume":"37","author":"Clark","year":"1995","journal-title":"Pediatric Research"},{"key":"10.1016\/j.bpg.2003.11.004_BIB95","series-title":"The effect of dose and composition of a pentavalent rotavirus reassortant vacine (RotaTeq\u2122) upon safety, efficacy and immunogenicity in healthy infants","author":"Vesikari","year":"2002"},{"key":"10.1016\/j.bpg.2003.11.004_BIB96","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1096-9071(199704)51:4<319::AID-JMV10>3.3.CO;2-L","article-title":"Construction of four double gene substitution human\u00d7bovine rotavirus reassortant vaccine candidates","volume":"51","author":"Hoshino","year":"1997","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB97","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/S0264-410X(98)00497-6","article-title":"Safety and immunogenicity of live attenuated human\u2013bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3, or 4 in adults, children and infants","volume":"17","author":"Clements-Mann","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB98","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1016\/S0264-410X(01)00242-0","article-title":"Safety and immunogenicity of live attenuated quadrivalent human\u2013bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants","volume":"19","author":"Clements-Mann","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB99","series-title":"Report of the meeting on the Future Directions for Rotavirus Research in Developing Countries. Geneva","year":"2000"},{"key":"10.1016\/j.bpg.2003.11.004_BIB100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/(SICI)1096-9071(199902)57:2<204::AID-JMV20>3.0.CO;2-Y","article-title":"Homotypic and heterotypic serum neutralising antibody response to rotavirus proteins following natural primary infection and re-infection in children","volume":"59","author":"Gorrell","year":"1999","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB101","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/infdis\/169.4.900","article-title":"Protection against rotavirus disease after natural infection","volume":"169","author":"Ward","year":"1994","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB102","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(98)12106-2","article-title":"Efficacy of live, attenuated human rotavirus vaccine 89\u201312 in infants: a randomised placebo-controlled trial","volume":"354","author":"Bernstein","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2003.11.004_BIB103","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/344732","article-title":"Second year follow-up evaluation of live, attenuated human rotavirus 89\u201312 vaccine in healthy infants","volume":"186","author":"Bernstein","year":"2002","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB104","series-title":"Evaluation of an oral human rotavirus (HRV) vaccine RIX4414 in Europe","author":"Vesikari","year":"2002"},{"key":"10.1016\/j.bpg.2003.11.004_BIB105","series-title":"Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants","author":"Perez-Schael","year":"2002"},{"key":"10.1016\/j.bpg.2003.11.004_BIB106","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1440-1754.1997.tb01604.x","article-title":"Phase I trial of a candidate rotavirus vaccine (RV3) derived from a human neonate","volume":"33","author":"Barnes","year":"1997","journal-title":"Journal of Paediatrics and Child Health"},{"key":"10.1016\/j.bpg.2003.11.004_BIB107","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/S0264-410X(02)00235-9","article-title":"Early phase II trial of human rotavirus vaccine candidate RV3","volume":"20","author":"Barnes","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.bpg.2003.11.004_BIB108","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1086\/340103","article-title":"The role of serum antibodies in the protection against rotavirus disease. An overview","volume":"34","author":"Jiang","year":"2002","journal-title":"Clinical infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/088282403763635410","article-title":"Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model","volume":"6","author":"Ward","year":"2003","journal-title":"Viral Immunology"},{"key":"10.1016\/j.bpg.2003.11.004_BIB110","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/374420","article-title":"The first rotavirus vaccine and intussusception. Epidemiological studies and policy decisions","volume":"187","author":"Murphy","year":"2003","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.bpg.2003.11.004_BIB111","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1542\/peds.110.6.e67","article-title":"Intussusception, rotavirus and other oral vaccines: Summary of a Workshop","volume":"110","author":"Peters","year":"2002","journal-title":"Pediatrics"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691803001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691803001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T18:19:59Z","timestamp":1623867599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691803001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S1521691803001513"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2003.11.004","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}